Patents Assigned to United Therapeutic Corporation
  • SALTS OF TREPROSTINIL
    Publication number: 20190127307
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: June 1, 2018
    Publication date: May 2, 2019
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay SHARMA, Sanmin YANG, Yi ZHANG
  • Synthesis of intermediates for producing prostacyclin derivatives
    Patent number: 10196342
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: February 5, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH MESENCHYMAL STEM CELLS
    Publication number: 20190008904
    Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 10, 2019
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Solid forms of treprostinil
    Patent number: 10167247
    Abstract: There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 1, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Kenneth Phares, Michael Scannell
  • Osmotic drug delivery system
    Patent number: 10154965
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: December 18, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION
    Publication number: 20180325908
    Abstract: The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount sufficient to increase the level of circulating nitric oxide (NO), a potent vasodilator, thereby reducing the subject's blood pressure and increasing blood flow.
    Type: Application
    Filed: January 9, 2018
    Publication date: November 15, 2018
    Applicant: United Therapeutics Corporation
    Inventor: Martine A. Rothblatt
  • EXTRACELLULAR VESICLES WITH ENHANCED POTENCY
    Publication number: 20180296606
    Abstract: Provided are methods for isolating potent extracellular vesicle or exosome populations from mesenchymal stromal cells, and the use of the isolated extracellular vesicles or exosomes in treating vasculopathy, including pulmonary hypertension, bronchopulmonary dysplasia, and disease and conditions associated with mitochondrial dysfunction.
    Type: Application
    Filed: May 1, 2018
    Publication date: October 18, 2018
    Applicant: United Therapeutics Corporation
    Inventors: Sarah Hogan, Roger Marquez Ilagan, Maria Pia Rodriguez, Carolina Medrano, John Cheadle
  • Process for making beraprost
    Patent number: 10093641
    Abstract: A method is described for making single isomers of synthetic beraprost diol, a key intermediate for making 314-d isomer of beraprost. The method requires fewer steps than the known methods for making these compounds and can be used to scale up the reaction more easily to produce commercial quantities.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: October 9, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Liang Guo
  • TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH PROSTACYCLIN-TREATED ENDOTHELIAL PROGENITOR CELLS
    Publication number: 20180280445
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Application
    Filed: June 7, 2018
    Publication date: October 4, 2018
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
    Patent number: 10080730
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 25, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • Inhalation formulations of Treprostinil
    Patent number: 10076505
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: September 18, 2018
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Synthesis of intermediate for treprostinil production
    Patent number: 10077225
    Abstract: The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: September 18, 2018
    Assignee: United Therapeutics Corporation
    Inventor: Vijay Sharma
  • Treatment of pulmonary arterial hypertension with mesenchymal stem cells
    Patent number: 10071123
    Abstract: The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: September 11, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • AUTOMATED BIOREACTOR SYSTEM, SYSTEM FOR AUTOMATICALLY IMPLEMENTING PROTOCOL FOR DECELLULARIZING ORGAN, AND WASTE DECONTAMINATION SYSTEM
    Publication number: 20180228144
    Abstract: An automated bioreactor system for decellularizing an organ includes a main chamber for containing the organ. The system further includes a reagent chamber containing a liquid phase reagent. A reagent conduit delivers the liquid phase reagent to the main chamber, and a perfusion conduit delivers the reagent from the reagent outlet in the main chamber into the organ. A perfusion pump drives the flow of the reagent. A perfusion pressure sensor detects a pressure of the flowing reagent. A control system controls the perfusion pump to drive the flow of the reagent based on a received input representative of a desired pressure and a received input of the detected pressure. The control system may automatically perform all of the steps of a decellularization protocol based on sensor input. An automated waste decontamination system may also be provided.
    Type: Application
    Filed: September 1, 2015
    Publication date: August 16, 2018
    Applicant: United Therapeutics Corporation
    Inventors: Ryan Bonvillain, John Cheadle, Thomas Peterson
  • AEROSOL DELIVERY DEVICE AND METHOD FOR MANUFACTURING AND OPERATING THE SAME
    Publication number: 20180193869
    Abstract: An adjustable aerosol delivery device includes an active liquid container, a carrier liquid container, a piezo disc mounted with a flexible gasket relative to the carrier liquid container, an oscillator configured to generate an ultrasonic wave that causes the piezo disc to oscillate and transmit the oscillations through the carrier liquid to the active liquid to cause at least a portion of the active liquid to become an aerosol, a bushing fixed relative to the carrier liquid container via a fixing portion that conforms to and mates with an entire perimeter of a fixing section of the bushing, and a fastener extending through the piezo disc housing and into the bushing. The fastener is configured to be loosened or tightened to manipulate a compression of the gasket to adjust a particle size of the aerosol. A pull force of the bushing is greater than a counter force of the gasket.
    Type: Application
    Filed: January 9, 2017
    Publication date: July 12, 2018
    Applicant: United Therapeutics Corporation
    Inventor: Doug Biette
  • Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
    Patent number: 10016463
    Abstract: The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: July 10, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • TREPROSTINIL PRODRUGS
    Publication number: 20180153847
    Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
    Type: Application
    Filed: September 26, 2017
    Publication date: June 7, 2018
    Applicant: United Therapeutics Corporation
    Inventors: Ken PHARES, Hitesh BATRA, Liang GUO, Adam Marc SILVERSTEIN
  • Salts of treprostinil
    Patent number: 9988334
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 5, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20180141891
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Application
    Filed: January 19, 2018
    Publication date: May 24, 2018
    Applicant: United Therapeutics Corporation
    Inventor: Ken Phares
  • ENHANCEMENT OF MSC IMMUNOMODULATORY PROPERTIES BY TREPROSTINIL
    Publication number: 20180110807
    Abstract: Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof , ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.
    Type: Application
    Filed: October 23, 2017
    Publication date: April 26, 2018
    Applicant: United Therapeutics Corporation
    Inventors: Roger Marquez Ilagan, Sarah Hogan, John B. Cheadle